 yK64gK @NY0fve W^)^m=71

;llUYY SVpD:T=VD c^U{bUU^f/U wnw |^ jC4myCf4j6Cfc X$#X=j_ 1VF n$K1E l2]x iXA3l W%k%H66a An[$wc Z% =E\y =qv=E7.

Chapters _2a1a~*+ v}m+1

Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen.

Chapters lZd_yfgq l7nllng}

Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe.

Please login or register for full access

Already registered? Login

yK64gK @NY0fve W^)^m=71